Abstract The Global Polio Eradication Initiative (GPEI) partners engaged modelers during
the past nearly 20 years to support strategy and policy discussions and decisions, and to …

Due to the very low, but nonzero, paralysis risks associated with the use of oral poliovirus
vaccine (OPV), eradicating poliomyelitis requires ending all OPV use globally. The Global …

Introduction Over the last 20 years (2000-2019) the partners of the Global Polio Eradication
Initiative (GPEI) invested in the development and application of mathematical models of …

Introduction: Ending all cases of poliomyelitis requires successful cessation of all oral
poliovirus vaccine (OPV), but the Global Polio Eradication Initiative (GPEI) partners should …

Introduction Detection of poliovirus transmission and ongoing oral poliovirus vaccine (OPV)
use continue to delay poliomyelitis eradication. In 2016, the Global Polio Eradication …

Globally coordinated cessation of all three serotypes of oral poliovirus vaccine (OPV)
represents a critical part of a successful polio endgame, which the Global Polio Eradication …

Nearly 20 years after the year 2000 target for global wild poliovirus (WPV) eradication, live
polioviruses continue to circulate with all three serotypes posing challenges for the polio …

Achieving global polio eradication requires that global stakeholders coordinate and
cooperate to invest human and financial resources in interventions that prevent virus …

After the globally coordinated cessation of any serotype of oral poliovirus vaccine (OPV),
some risks remain from undetected, existing homotypic OPV‐related transmission and/or …

The oral polio vaccine (OPV) contains live-attenuated polioviruses that induce immunity by
causing low virulence infections in vaccine recipients and their close contacts. Widespread …